NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
7 trialsNCT05085977 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT05085990 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed
NCT01316874 2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT00141531 2012-06-14
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed